Montironi R - Search Results

1

Renal tumors: diagnostic and prognostic biomarkers.

Tan PH, Cheng L, Rioux-Leclercq N, Merino MJ, Netto G, Reuter VE, Shen SS, Grignon DJ, Montironi R, Egevad L, Srigley JR, Delahunt B, Moch H; ISUP Renal Tumor Panel. Tan PH, et al. Among authors: montironi r. Am J Surg Pathol. 2013 Oct;37(10):1518-31. doi: 10.1097/PAS.0b013e318299f12e. Am J Surg Pathol. 2013. PMID: 24025522 Free PMC article.

2

Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation.

Lopez-Beltran A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, Sesterhenn I, van det Kwast KT, Mazerolles C. Lopez-Beltran A, et al. Among authors: montironi r. Virchows Arch. 2002 Jan;440(1):3-11. doi: 10.1007/s00428-001-0577-6. Virchows Arch. 2002. PMID: 11942574 Review.

3

Evaluation of prognostic factors in radical prostatectomy specimens with cancer.

Mazzucchelli R, Santinelli A, Lopez-Beltran A, Scarpelli M, Montironi R. Mazzucchelli R, et al. Among authors: montironi r. Urol Int. 2002;68(4):209-15. doi: 10.1159/000058437. Urol Int. 2002. PMID: 12053019 Review.

4

Improving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network.

Montironi R, Mazzucchelli R, Colanzi P, Streccioni M, Scarpelli M, Thompson D, Bartels PH. Montironi R, et al. Eur Urol. 2002 Apr;41(4):449-57. doi: 10.1016/s0302-2838(02)00028-3. Eur Urol. 2002. PMID: 12074818

5

Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention.

Montironi R, Mazzucchelli R, Scarpelli M. Montironi R, et al. Ann N Y Acad Sci. 2002 Jun;963:169-84. doi: 10.1111/j.1749-6632.2002.tb04108.x. Ann N Y Acad Sci. 2002. PMID: 12095942

6

Frequent FGFR3 mutations in urothelial papilloma.

van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH. van Rhijn BW, et al. Among authors: montironi r. J Pathol. 2002 Oct;198(2):245-51. doi: 10.1002/path.1202. J Pathol. 2002. PMID: 12237885

7

TP53 in urologic tumors.

Algaba F, Trias I, Santinelli A, Montironi R. Algaba F, et al. Among authors: montironi r. Anal Quant Cytol Histol. 2003 Jun;25(3):123-30. Anal Quant Cytol Histol. 2003. PMID: 12882083 Review.

8

Molecular techniques and prostate cancer diagnostic.

Montironi R, Mazzucchelli R, Scarpelli M. Montironi R, et al. Eur Urol. 2003 Oct;44(4):390-400. doi: 10.1016/s0302-2838(03)00309-9. Eur Urol. 2003. PMID: 14499671 Review.

9

Subvisual changes in chromatin organization state are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma.

Montironi R, Scarpelli M, Mazzucchelli R, Hamilton PW, Thompson D, Ranger-Moore J, Bostwick DG, Bartels PH. Montironi R, et al. Hum Pathol. 2003 Sep;34(9):893-901. doi: 10.1016/s0046-8177(03)00341-1. Hum Pathol. 2003. PMID: 14562285

10

Androgen ablation therapy for prostate carcinoma suppresses the immunoreactive telomerase subunit hTERT.

Iczkowski KA, Huang W, Mazzucchelli R, Pantazis CG, Stevens GR, Montironi R. Iczkowski KA, et al. Among authors: montironi r. Cancer. 2004 Jan 15;100(2):294-9. doi: 10.1002/cncr.20002. Cancer. 2004. PMID: 14716763 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,020 results

Search Page

Filters